Monday, 15. December 2014

IDT Biologika places third for the 2014 Hugo Junkers Innovation Award

IDT Biologika is sharing the 2014 Hugo Junkers Innovation Award in the Applied Research category with its innovative production process for a recombinant live vaccine. Andreas Neubert, Director of the IDT Biologika Vaccines Business Unit, and his team of ten, have developed a process for producing live vaccines significantly faster and in large volumes.

This innovation was honored with the third-place Hugo Junkers Innovation Award in Magdeburg on December 15. A total of 122 applicants submitted their innovative projects and products. The Hugo Junkers Innovation Award is sponsored by the Saxony-Anhalt Ministry for Science and the Economy.

Together with Dr. Andreas Neubert, Angela Höer, Sabrina Pelz and Frances Wolf (from left) accepted the award on behalf of IDT in Magdeburg. MDR moderator Susi Brandt interviewed the winning teams on stage.
Together with Dr. Andreas Neubert, Angela Höer, Sabrina Pelz and Frances Wolf (from left) accepted the award on behalf of IDT in Magdeburg. MDR moderator Susi Brandt interviewed the winning teams on stage.

Due to its high level of purity, the vaccine produced using the new process minimizes undesirable side effects such as allergic or shock reactions. Vaccine has already been made available for clinical trials. Precise dosage, efficacy and possible side effects are currently being investigated in human clinical trials, with a view to the vaccine’s authorization.

The virus vaccine itself was produced in Canada with IDT participation using a biomolecular process. “Using genetic technology, today we can do away with tedious cultivation, and instead remove the harmful gene sequences from a virus vaccine and extract carrier particles containing the desired antigens,” explains Dr. Andreas Neubert, Director of IDT Biologika’s global vaccine business.

The weakened, genetically modified virus vaccine is then bred in cell cultures. This requires nourishment. Instead of feeding the cells with animal serums as in conventional processes, the scientists utilize chemically defined nutrient solutions. They use exclusively disposable materials, and achieve a yield of active agent without losses using a specially developed purification procedure with comparably little technical input. The share of unwanted corollary materials is reduced to well below the legally required minimum.

“Large volumes of emergency vaccine can be prepared in a short time using our process,” stresses Dr. Andreas Neubert. IDT plans to launch its own production using the new process itself, as well as manufacture live vaccines upon customer order.

News Overview

Positive interim summary of strategic realignment at CPhl trade fair:

IDT Biologika Awarded new Task Order to Manufacture Vaccines and Biologics for Infectious Diseases

IDT Biologika inaugurates new multifunctional production facility for vaccines at BioPharmaPark area

Ceva completes acquisition

IDT Biologika to concentrate on human vaccines and pharmaceuticals

Ceva Santé Animale and IDT Biologika GmbH

CMO Leadership Awards 2019

IDT Biologika Awarded 10-Year NIH Contract

CEPI Awards Contract Worth Up To USD$36 million to Consortium led by IDT to Develop MERS Vaccine

25th anniversary of the privatization of IDT Biologika